VIR · Vir Biotechnology, Inc.

Vir Biotechnology reported GAAP revenue of -$29 thousand for Q1 2026, a 101% decline from $3.0 million in the prior-year quarter. This sharp drop occurred because grant revenue decreased primarily due to lower recognition under the agreement with the Gates Foundation, while other revenue fell from reduced sales of clinical supply to Brii Biosciences Limited. These dynamics reflect the lumpy nature of biotech revenue tied to specific grants and milestone-based collaborations, leaving the company more reliant on cash reserves to fund operations.

The GAAP operating loss narrowed to $132.3 million from $139.5 million year-over-year, a 5.2% improvement. This moderation stems from the company's management of research and development expenses, which are recognized as incurred. Prepayments for R&D goods and services are capitalized until received, providing some timing flexibility. Investors should note that while losses persist, the year-over-year progress indicates cost discipline amid a high-burn biotech model focused on advancing clinical candidates.

Net loss widened slightly to $125.7 million from $120.965 million, or 3.9% worse year-over-year, with diluted EPS at -$0.85 versus -$0.88. Other expense, net—which includes foreign currency gains/losses and investment management costs—contributed to this movement. Interest income also declined due to lower cash, equivalents, and investment balances alongside reduced rates, underscoring balance sheet pressures as the company deploys capital into pipeline programs.